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Abstract:   
 
Introduction: Cardiovascular (CV) disease is a major cause of reduced life expectancy in 
type 1 diabetes (T1D).  Intensive insulin therapy prevents CV complications but is 
constrained by hypoglycaemia and weight gain.  Adjunct metformin reduces insulin dose 
requirement and stabilises weight but there are no data on its cardiovascular effects.   
Aims: We have initiated an international double-blind, randomized, placebo-controlled trial 
(REMOVAL: REducing with MetfOrmin Vascular Adverse Lesions in type 1 diabetes) to 
examine whether metformin reduces progression of atherosclerosis in adults with T1D.  
Individuals ≥40 years of age with T1D for ≥5 years are eligible if they have ≥3 of 10 
specified CV risk factors.  The enrolment target is 500 participants in 17 international centres.   
Materials and Methods: After 12 weeks single-blind placebo-controlled run-in, participants 
with >70 % adherence are randomized to metformin or matching placebo for three years with 
insulin titrated towards HbA1c 7.0% (53 mmol/mol)].  The primary endpoint is progression 
of averaged mean far wall common carotid intima-media thickness (cIMT) measured by 
ultrasonography at baseline, 12, 24 and 36 months.  This design provides 90% power to 
detect a mean difference of 0.0167 mm in cIMT progression between treatment arms 
(α=0.05), assuming up to 20% withdraw or discontinue treatment. Other endpoints include 
HbA1c, weight, LDL cholesterol, insulin requirement, progression of retinopathy, endothelial 
function and frequency of hypoglycaemia.   
Results and Conclusions: REMOVAL is the largest clinical trial of adjunct metformin 
therapy in T1D to date and will provide clinically meaningful information on its potential to 
impact CV disease and other complications. 
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Introduction 
Period life expectancy in people with type 1 diabetes (T1D) is reduced by 11-13 years (1); 
rates of CV events are at least double those in the general population and account for ≈45% 
of deaths (2).  Long-term post-randomisation data from the Diabetes Control and 
Complications Trial (DCCT) participants followed up in the Epidemiology of Diabetes 
Interventions and Complications (EDIC) study demonstrate that intensive diabetes control 
reduces both microvascular and CV complications in T1D (3).  
However, in population-based data only around 30% of individuals with T1D are near 
target HbA1c (< 7.5%/ 59 mmol/mol) and at least 30% have poor control (HbA1c ≥ 9.0%/ 75 
mmol/mol) (4).  A key barrier to optimising glycaemia is hypoglycaemia: in the DCCT, rates 
of severe hypoglycaemia were threefold higher in those randomised to intensive therapy and 
with HbA1c at or below target (5).  Another long-term issue is insulin-induced weight gain, 
which may be accompanied by escalating insulin dose requirements, increased LDL 
cholesterol and/or raised blood pressure (BP) (6-8).  
Adjunct therapy with metformin reduces insulin dosage in T1D and may attenuate 
weight gain (9-13); some clinicians already use it in this context.  As metformin reduces CV 
disease in type 2 diabetes (T2D) (14-16), and is recommended first-line therapy in most 
international guidelines (17), we hypothesized that it might also provide CV protection in 
T1D.   
In this largest and longest trial of metformin in T1D to date, we aim to gather data on 
cardiovascular and metabolic endpoints as well as key aspects of long-term safety (e.g. 
vitamin B12 status, lactic acidosis).  Progression of carotid artery intima-media thickness 
(cIMT) measured by ultrasonography is the primary endpoint as it was reduced by intensive 
glucose control in DCCT-EDIC (18): this was later validated by reduced CV events (3).   
Materials and Methods  
Objectives and endpoints    
The primary objective of the REducing with MetfOrmin Vascular Adverse Lesions in type 1 
diabetes (REMOVAL: clinical trials.gov NCT01483560) is to test in adults with T1D 
whether metformin added to insulin therapy (titrated towards target HbA1c 7.0%/ 53 
mmol/mol) reduces progression of atherosclerosis in the common carotid artery (CCA) 
defined as within-person change in bilateral averaged mean far wall carotid intima-media 
thickness (cIMT) measured annually over three years.  
For measurement of cIMT, the same ultrasound system and pre-set image parameter 
settings (e.g. depth, gain, persistence, dynamic range, post processing) are to be maintained at 
each site throughout the study. The reading centre [University College London (UK)] trains 
each site sonographer who then submits five accreditation scans.  Right and left carotid 
arteries are interrogated in B mode with a 7.0 MHz or higher broadband linear array 
transducer with concurrent recording of a three lead ECG.  A plaque screen (defined as focal 
thickening ≥1.5 mm or 50% greater than surrounding IMT) of the near and far walls of the 
CCA, bulb and internal carotid artery segments is also performed.  Longitudinal images of 
the CCA are obtained at anterior, lateral and posterior angles using Meijer’s arc during at 
least five cardiac cycles.  Additional cIMT measurements are performed on a panel of six 
participants at each site annually to monitor reproducibility.  At the reading centre, triplicate 
measurements are taken from the distal centimetre of the CCA (i.e. immediately proximal to 
the bulb) by a single trained assessor using a validated semi-automated program (19). The 
assessor undergoes repeated ‘masked’ QC cycles to assess repeatability.    
For the assessment of retinal disease, two colour 45° field photographs (field 1 optic 
disc; field 2, macula) are taken in each eye at randomisation and 36 months.  In the UK these 
are acquired directly from national retinal screening systems.  Images are graded using 
custom designed software at the University of Wisconsin Ocular Epidemiology Reading 
Center (OERC) using the modified Airlie House classification scheme and the Early 
Treatment Diabetic Retinopathy Severity scale as previously described (20).  Component 
retinal lesions are evaluated individually.  If significant retinal pathology exists, the site 
Principal Investigator is notified to ensure appropriate clinical action. 
Endothelial function is assessed in centres covering 80% of participants using 
peripheral Arterial Tonometry (ENDOPAT, Itamar, Israel) to measure Reactive Hyperaemia 
Index (RHI) non-invasively at 0, 12 and 36 months.  This method assesses changes in digital 
pulse volume and pulse wave velocity (21).   ENDOPAT studies are reviewed by Itamar staff 
and scan quality reported back to site staff within one week.  
Other secondary and tertiary endpoints are shown in Table 1.  Each of the secondary 
outcome measures will be analysed separately and the individual results will be reported.   
The protocol has a pre-defined composite interpretation of the secondary outcomes where 
results will be considered clinically meaningful with the potential to influence clinical 
practice in the event that a statistically significant improvement in two or more of the 
following individual outcomes is observed on metformin : (i) HbA1c (by DCCT-standardised 
local assays); (ii) LDL-cholesterol (centrally-measured); (iii) albuminuria [based on at least 
two separate urine specimens and routinely available assays – see Supplementary Information 
(c)]; (iv) two or more step progression on the 11-step modified concatenated retinopathy 
severity scale; (v) weight (by calibrated scales); (vi) insulin dose; (vii) and endothelial 
function (RHI). 
Trial management 
The protocol was approved by the West of Scotland Research Ethics Service (REC1) (UK) 
and Medical Research Ethics Committees/Institutional Review Boards: St Vincent’s Hospital 
and Royal Melbourne Hospital (Melbourne) and Royal Prince Alfred Hospital (Sydney) 
[Australia]; Western University Health Science Research Ethics Board [Canada]; 
Hovedstaden Region Centre of Health [Denmark]; and Maastricht University Medical Centre, 
Maastricht [Netherlands].   Trial governance and oversight is the responsibility of the co-
sponsors [University of Glasgow and Greater Glasgow and Clyde Health Board (UK)] with 
trial monitoring outside the UK and Denmark delegated by agreement to national partner 
institutions. Active and matching placebo study medications are provided by Merck KGaA 
(Darmstadt, Germany) free of charge.  All scans and photographs are uploaded by site 
personnel via a purpose-designed electronic Case Report Form (eCRF) on to a secure server 
at the University of Glasgow for digital archiving and later download for analysis at reading 
centres.  Data management is by the Robertson Centre for Biostatistics, University of 
Glasgow.  An Independent Data Monitoring Committee (IDMC) reviews six monthly 
unmasked reports on study progress.  Seventeen initial and five reserve sites with expertise in 
cIMT measurement have been selected across the UK, Australia, Canada, Denmark and the 
Netherlands.   Where long-term post-randomisation follow-up is permitted, we seek consent 
from participants for the local team to remain in contact at trial end.  
Screening, eligibility, enrolment and run-in period 
Individuals aged ≥40 years with ≥5 years T1D and at least three of 10 specified CV risk 
factors are eligible (Table 2).  T1D is defined as diagnosis of diabetes before age 35 years and 
insulin use within one year.  Potential participants are approached by mail or in person at 
regular clinic visits; those expressing an interest are given further information and invited to 
return to a (non-fasting) screening visit.   
Following informed consent, past medical history, family history, and concomitant 
medication (including duration, type and dose of any previous statin and/or ACE inhibitor 
therapy) are recorded on the eCRF.  Height, body weight, ethnicity, and smoking status are 
documented; blood pressure (BP) and heart rate are measured in triplicate according to 
Standard Operating Procedures specified in the Protocol.  The Steno Hypoglycaemia 
questionnaire (Supplementary Materials) and the Diabetes Treatment Satisfaction 
Questionnaire (DTSQ) (22) are administered.  Blood and urine samples are sent to local 
laboratories for measurement of HbA1c, serum lipids, liver function tests, albuminuria, renal 
function (unless results are available from the previous 90 days), and random C-peptide.   
Aliquots of serum, plasma, urine and buffy coat are retained for biomarker assays and later 
DNA extraction.  Cholesterol and BP lowering therapies are reviewed against local standard 
of care and treatment adjusted as indicated.  Urine for pregnancy testing is requested from 
women of childbearing potential who are not using an effective method of contraception at 
this (and all subsequent) in-person visits with a view to discontinuing study medication if the 
test is positive.   
Enrolled participants are invited to enter a three-month run-in period and issued with 
single-blind placebo tablets (matching metformin 500mg) to take once daily with the evening 
meal during the third month only (Figure 1).  The first of a series of dedicated study diaries is 
provided containing guidance on study medication dose titration, adverse effects and “sick 
day rules” as well as contact details for the local study team.  Space is provided for structured 
recording of insulin doses and four-point blood glucose profiles during the three days prior to 
each scheduled telephone or in-person visit.  Participants are also asked to record all changes 
in concomitant medication.  
Individual insulin regimens are reviewed by site staff at the beginning of the run-in 
period with a view to making any changes required to facilitate optimisation of control (target 
HbA1c 7.0%/ 53 mmol/mol).  Additional “in person” clinic visits are arranged if necessary.  
Structured telephone visits are conducted approximately monthly during the remainder of the 
run-in for review of blood glucose monitoring data and insulin doses; this support remains 
available throughout the trial.   
Randomisation and follow-up 
A randomisation visit (fasting) is scheduled at the end of the run-in period.  Participants with 
≥ 70% adherence and a screening visit C-peptide ≤ 0.2 nmol/L undergo baseline study 
measurements including cIMT, endothelial function and retinal photographs.  Randomisation 
is by an Interactive Voice Response System (IVRS) hosted by the Robertson Centre for 
Biostatistics. Double-blind study medication (metformin as Glucophage 500 mg® or 
matching placebo) is issued in identical packages covering three or six month periods 
according to the visit schedule.   
 Participants are asked to carry a Patient Alert Card containing details of emergency 
unmasking procedures.   Following randomisation, they are asked to uptitrate their dose of 
study medication on a weekly basis from one tablet daily with the evening meal in week 1, to 
two tablets per day (with breakfast and evening meal) in week 2, until the target dose of two 
tablets with each of these meals (equivalent to 1000 mg twice daily) is achieved in week 4. 
Dose titration is supported by weekly telephone visits; dose downtitration or treatment 
interruption (e.g. in response to gastrointestinal adverse effects) is permitted at any time 
during the trial.  If treatment interruption persists for more than four weeks, site staff are 
instructed to record a permanent treatment discontinuation.  Treatment restart is encouraged 
at any time if appropriate at the discretion of the site Principal Investigator.  Current dose is 
recorded at each in-person visit with tablet counts conducted by site staff.  
As far as possible, study visits are designed to coincide with appointments in routine 
care; repeat assessments of the main study endpoints and other items are conducted at 12, 24 
and 36 months (Table 3).  During the trial all participants continue to have access to usual 
local arrangements for diet and lifestyle advice along with weight management.  Ongoing 
glycaemia, BP and cholesterol management are under the care of the site PI and usual care 
team according to updated national and international guidelines.  
Hypoglycaemia 
Participants are asked to record all symptomatic or biochemically-proven hypoglycaemic 
episodes (<2.8.mmol/l; 50 mg/dL) in the Study Diary.  This information is used by site nurses 
at follow-up visits as a basis for completing the Steno Hypoglycaemia Questionnaire in 
which events are categorised as: minor (self-treated, resolved with short acting glucose and 
longer acting carbohydrate); major (requiring assistance from one or more other persons); or 
major with unconsciousness (self-reported). 
Safety and pharmacovigilance  
Hepatic and renal function are monitored at all in-person visits.  Permanent discontinuation of 
study medication is mandated in cases of significant hepatic (alanine transaminase >3.0 times 
upper limit of normal) or renal (eGFR <30 mL/min/1.73m2) impairment.  Investigators are 
advised to reduce study medication dose to one tablet twice daily in all participants in whom 
eGFR falls below 45 mL/min/1.73m2 during follow-up.  Serum lactate is checked at baseline 
and annually: study medication is permanently discontinued if a single measurement is >5.0 
mmol/L with acidosis (including in routine clinical care) or if a level >3.0 mmol/L is 
sustained on a mandated repeat sample within one week.  Vitamin B12 levels are monitored 
annually: participants in whom levels fall below 150 pmol/L are offered the choice of 
treatment discontinuation or referral back to primary care for injectable supplements.   
In addition to Serious Adverse Event reporting, specific gastrointestinal, neurological, 
metabolic, renal and cardiovascular Adverse Events of Medical Interest are also recorded, as 
well as new diabetes-related complications, operations or procedures. 
Following each meeting of the IDMC (see above), a recommendation is made to the 
co-sponsors regarding the appropriateness of continuing the trial from a safety and efficacy 
perspective.  In addition to these arrangements, a Glycaemia Committee led by Dr Irene 
Hramiak (Ontario, Canada) sends detailed blinded reports on participants’ HbA1c and rates 
of hypoglycaemia to each site every six months along with “benchmarking” data from other 
sites in their region.  The Committee can contact and support centres in which average 
HbA1c is higher than in other comparable centres.   
 
Statistical considerations 
All analyses will be conducted blinded to treatment allocation.  The principal analysis will be 
on a modified intention to treat analysis set i.e. include all subjects from the intention to treat 
population (all randomized participants, regardless of subsequent participation in the study) 
with data available (without imputation).  The target sample size is based on analysing the 
cIMT primary endpoint data using repeated measures regression analysis assuming a linear 
progression in the control arm of mean 0.044mm and standard deviation (SD) 0.050 mm over 
three years (23). Regression model effect estimates with 95% confidence intervals and 
associated p-values will be calculated.  In order to minimise the residual SD, cIMT data will 
be adjusted for baseline cIMT as well as for age, sex and baseline levels of cardiovascular 
risk factors predictive of cIMT progression (specified in the Statistical Analysis Plan).  To 
account for differences in ultrasound machines used at sites, a sensitivity analysis adjusting 
for ultrasound probe frequency is also specified along with a separate per protocol analysis.   
A final sample size of 200 participants per treatment arm provides 90% power to 
detect an average mean cIMT difference of at least 0.0167mm (one third of an SD) between 
treatment arms (α=0.05): we therefore aim to recruit 500 patients allowing for 20% treatment 
withdrawal and/or treatment discontinuation.  This sample size will provide 90% power to 
detect differences of approximately 0.3 SD in secondary endpoints including lipid, metabolic 
and endothelial function (α=0.05).  The retinopathy secondary endpoint is exploratory: if 
three year two-step progression in ETDRS category is estimated at 13.7%, treatment with 
metformin will have to be associated with 60% reduction in risk for 80% power to declare 
significance at p<0.05.  No interim analyses are planned or pre-specified. 
 
Results and Discussion  
REMOVAL is the first adequately-powered long term trial of the impact of metformin on a 
valid CV surrogate outcome (cIMT) in T1D.  It will also collect data on metabolic endpoints 
(insulin dose, weight, HbA1c, hypoglycaemia, LDL cholesterol) as well as other vascular 
outcomes (endothelial function, retinal disease).  
Metformin is a biguanide that undergoes active transport via cationic transporters and 
accumulates in intestinal cells (24). During steady state oral therapy, plasma glucose is 
reduced mainly by inhibition of hepatic glucose production (25).  Glucose-lowering is key to 
reducing microvascular complications in both T1D and T2D, but its effect on cardiovascular 
(macrovascular) complications is more complex, as other risk factors impact to a greater or 
lesser extent.   
The differing molecular mechanisms of action of the various available classes of 
glucose-lowering “antidiabetic” agents are critical to their overall therapeutic profile as 
candidates for adjunct therapy.   For metformin, mechanisms relevant to glucose-lowering 
include activation of AMP-activated protein kinase (AMPK) (26), inhibition of mitochondrial 
glycerophosphate dehydrogenase (27), and release of gut hormones (including glucagon like 
peptide-1) (28).  However, other downstream effects of AMPK have been postulated to 
mediate vascular actions of metformin (29), including modulation of proinflammatory 
pathways in perivascular adipose tissue (30) and inhibition of STAT3 (and thereby monocyte 
to macrophage differentiation) in vascular tissue (31).  Moreover, metformin can inhibit 
advanced glycosylation end products (AGEs) formation by binding and inactivating 
methyglyoxal via an AMPK-independent pathway (32). 
 The primary focus of REMOVAL is to assess metformin’s effects on the 
cardiovascular system in adults with T1D at high risk of CV disease rather than its ability to 
lower glucose.  Accordingly, we adopted a double-blind, placebo-controlled, “treat to target 
HbA1c” design.  When adjunct agents are prescribed in T1D insulin doses are often down-
titrated to avoid hypoglycaemia such that an overall effect on glycaemia (measured by 
HbA1c) is not sustained (10, 11 13).  Thus, although HbA1c is one of seven pre-specified 
secondary endpoints, it is unlikely by design that a sustained separation in glycaemia between 
active and placebo arms will be observed.  Instead, the trial is powered to detect whether 
three years of metformin reduces atherosclerosis progression as measured by cIMT.  In 
addition to measuring vascular structure, we are assessing endothelial function (RHI) in 80% 
of participants to provide an index of vascular function.   
cIMT can be considered a validated surrogate endpoint for atherosclerotic disease in 
T1D on the basis of DCCT-EDIC (3, 18).  However, despite the variety of pathways by 
which metformin has been hypothesised to exert potentially beneficial effects on the 
cardiovascular system (29-31), there is conflicting evidence regarding its effects on cIMT.  
We recently reported that metformin had no impact on cIMT over 18 months in non-diabetic 
patients with established coronary heart disease (33); similarly, no reduction in cIMT 
progression was detected in insulin-treated people with T2D in the recent (underpowered) 
Copenhagen IMT trial (34).  However, metformin has been reported to reduce cIMT 
progression in metabolic syndrome (35) and also in T2D (36).  REMOVAL is the first cIMT 
progression trial in T1D; in this context it is important to note that mechanisms of accelerated 
atherosclerosis in T1D and T2D differ in a number of aspects (37, 38).   
Despite a paucity of evidence in T1D, metformin (embonate) already holds a product 
license for use in T1D in France (39); moreover, the UK National Institute for Clinical 
Excellence (NICE) recently recommended metformin for adults with T1D and BMI ≥ 25 
kg/m2 who “want to improve glucose control while minimising their effective insulin dose” 
(40).  Currently more than 50% of people with T1D are now obese or overweight (8). Given 
that REMOVAL is planned to be three times longer and larger than any previous T1D 
metformin trial, the secondary endpoint data will be of considerable clinical utility in 
addressing longer term metabolic effects (e.g. on weight and insulin dose). 
As metformin is structurally related to phenformin, which was withdrawn in the 
1970s due to cases of lactic acidosis, concerns have been expressed regarding its use in 
ketoacidosis-prone T1D patients (41).  Metformin is commonly associated with 
gastrointestinal adverse effects, and long-term use in T2D is associated with vitamin B12 
deficiency (42,43).  Rather than simply extrapolating its adverse effect profile and overall 
tolerability from T2D, REMOVAL will gather important specific safety data on metformin in 
T1D.  
A key study limitation is use of a surrogate primary endpoint rather than clinical 
cardiovascular events (44).  Although several large T2D CV outcome trials have reported 
recently and many more are in progress (45), not a single randomized trial of any intervention 
with CVD as the primary outcome has been performed in T1D to date, despite the undoubted 
impact of CV disease in this condition (1, 2).  Much of the current evidence base for CV 
preventive strategies in T1D (including for statins) is extrapolated from T2D or from meta-
analysis of T1D subgroups (46, 47).  Another limitation is that focusing on atherosclerosis 
progression in the carotid artery may obviate detection of any beneficial cardiovascular 
effects mediated by other mechanisms. Data on which to base estimates of degree of cIMT 
disease and rate of change in our population were limited (mainly from DCCT) and thus there 
remains a degree of uncertainty in the power of a three year intervention study in this 
population.  Finally, the retinal endpoint can only be regarded as exploratory; it was included 
to acquire a point estimate for any likely effect size to guide future research given the 
relatively low marginal cost of acquiring images from routine screening (at least at UK sites). 
Two different glucose-lowering agents used in T2D have recently been demonstrated 
to improve cardiovascular outcomes: a GLP-1 agonist (48) and an SGLT2 inhibitor (49).  We 
anticipate that our international effort in REMOVAL, the largest and longest clinical trial of 
adjunct metformin therapy in T1D to date, will illustrate the feasibility of conducting large 
collaborative multi-centre cardiovascular trials of adjunct therapy in T1D.  Whether the data 
for metformin in the REMOVAL trial are positive or negative, we hope they will provide a 
stimulus to funding agencies and the wider diabetes community to support timely trials of 
other adjunct therapy candidates with the twin aims of improving metabolic control and CV 
outcomes.  Agents which can reduce rates of CV disease are urgently needed in T1D. 
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Figure Legends  
 
Figure 1: Outline of protocol   
Table 1: Study endpoints 
 
Change from baseline compared between treatment groups: 
 
 
Primary:  
 
Progression of averaged mean far wall common carotid artery IMT (CCA cIMT, measured in mm, at 
baseline, 12, 24 and 36 months).   
 
 
Secondary:   
 
(i) HbA1c (site DCCT-aligned laboratories)  
(ii) LDL-cholesterol (central lab) 
(iii) albuminuria1  
(iv) retinopathy stage (two step progression on the ETDRS scale)  
(v) weight 
(vi) insulin dose  
(vii) endothelial function (in at least 80% of participants)  
 
Composite interpretation of all secondary endpoints: 
 
Improvement in two or more of these secondary endpoints will be considered clinically meaningful 
with the potential to influence clinical practice. 
 
 
Tertiary:  
 
(i) frequency of hypoglycaemia (modified Steno Hypoglycaemia Questionnaire);  
(ii) treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire);  
(iii) markers of endothelial function (t-PA, sE-selectin, sICAM-1);  
(iv) progression of averaged maximal distal common carotid artery IMT (CCA cIMT, measured in 
mm, at baseline, 12, 24 and 36 months).   
(v) vitamin B12 status 
 
1time to event analysis using a Cox Proportional Hazards Model. 
 
  
Table 2:  Entry criteria*  
 
Inclusion: 
 
Type 1 diabetes for five years or more;1  
age ≥ 40 years;  
7.0 ≤ HbA1c < 10.0% (53-86 mmol/mol)  
 
AND: 
 
three or more of the following 10 CVD risk 
factors: 
 
1. BMI ≥ 27 kg/m2 
2. current HbA1c > 8.0% (64 mmol/mol) 
3. known CVD/ peripheral vascular disease 
4. current smoker 
5. eGFR < 90 ml/ min/ 1.73 m2 
6. confirmed micro- (or macro-) 
    albuminuria2  
7. hypertension (BP≥140/ 90 mmHg; or 
    established antihypertensive treatment) 
8. dyslipidaemia3  
9. strong family history of CVD4 
10. duration of diabetes > 20 years. 
 
 
 
Exclusion: 
 
1. eGFR <  45 ml/ min/ 1.73m2 
2. woman of childbearing age not on effective 
contraception 
3. pregnancy and/or lactation  
4. Acute Coronary Syndrome or Stroke/ TIA 
within the last 3 months  
5. NYHA stage 3 or 4 heart failure  
6. uncontrolled angina 
7. significant hypoglycaemia unawareness5 
8. impaired cognitive function/ unable to give 
informed consent 
9. previous carotid surgery/ inability to capture 
adequate carotid images 
10. gastroparesis5  
11. history of lactic acidosis 
12. other contraindications to metformin 
- hepatic impairment 
- known hypersensitivity to metformin 
- acute illness (dehydration, severe   
    infection, shock, acute cardiac failure) 
- suspected tissue hypoxia 
13. any coexistent life threatening condition 
including prior diagnosis of cancer within two 
years  
14. history of alcohol problem or drug abuse 
 
 
*abbreviated from full Protocol Version 1.0 
 
1defined as diagnosis below age 35 years AND insulin use within 1 year of diagnosis 
2as judged by the site Principal Investigator based on at least two urine samples assayed locally and interpreted according 
to site reference ranges [see Supplementary Information (c)] 
3total cholesterol ≥ 5.0 mmol/L (200 mg/dL); or HDL cholesterol < 1.2 mmol/L (46 mg/dL) [men] or < 1.3 mmol/L (50 
mg/dL) [women]; or triglycerides ≥ 1.7 mmol/L (150 mg/dL); or established on lipid-lowering treatment 
4at least one parent, biological aunt/ uncle, or sibling with myocardial infarction,(coronary artery bypass graft added at Proto
Amendment 2.0) or stroke aged < 60 years) 
5confirmed as significant by site Principal Investigator 
 
 
  
Table 3:  Schedule of visits (abbreviated) 
Activity  Run-In  Period Randomize Months 
Month Screen - 12 weeks 0   1 3 6 9 12 15 18 21 24 27 30 33 36  
*telephone visit  
F fasting visit 
Visit 
R1 
Visit 
R2* 
Visit 
R3* 
Visit 
R4* 
Visit 
1F 
Visit 
2* 
Visit 
3* 
Visit 
4* 
Visit 
5   
Visit 
6  
Visit 
7 * 
Visit 
8 F 
Visit 
9* 
Visit 
10 
Visit 
11* 
Visit 
12 F 
Visit 
13* 
Visit 
14  
Visit
15* 
Visit 
16 F 
Close
out 
Informed consent x                     
Randomization     x                 
Current medications  x    x   x x x x x  x  x  x  x  
Height, weight x    x    x x  x  x  x  x  x  
Assess insulin dose  x x x x x x x x x x x x x x x x x x x x 
Questionnaires  x    x   x x x x x x x x x x x x x  
Blood Samples x    x    x x  x  x  x  x  x  
Pregnancy test x    x Repeated if applicable 
Carotid IMT      x       x    x    x  
Retinal images      x               x  
Endothelial function*  
some centres only 
    x       x        x  
Urine sample X    X       X    X    x  
Dispense study 
medication 
x    x    x x  x  x  x  x    
 
* = telephone visit
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